Aldoxorubicin: Phase Ib started

CytRx began an open-label, dose-escalation, U.S. Phase Ib trial to evaluate 170, 250 and 350 mg/m 2 IV aldoxorubicin given on day 1 of a 21-day cycle plus gemcitabine in up to 30 patients with metasta...